ABSTRACT
Boletim com o objetivo de demonstrar o perfil epidemiológico dos casos que foram notificados entre 2019 a 2023, apresentando os indicadores epidemiológicos e operacionais de relevância do estado, para fins de tomada de decisão em relação às ações do Programa para Eliminação das Hepatites Virais até 2030. Trata-se de uma análise de dados secundários obtidos do Sistema de Informação de Agravos de Notificações (SINAN), referentes aos casos diagnosticados e notificados, por município de residência entre 2019 e 2023 pelos serviços de saúde do Estado de Goiás
Bulletin with the aim of demonstrating the epidemiological profile of cases that were reported between 2019 and 2023, presenting epidemiological and operational indicators of relevance to the state, for decision-making purposes in relation to the actions of the Program for the Elimination of Viral Hepatitis by 2030. This is an analysis of secondary data obtained from the Notifiable Diseases Information System (SINAN), referring to cases diagnosed and notified, by municipality of residence between 2019 and 2023 by the health services of the State of Goiás
Subject(s)
Humans , Hepatitis/epidemiology , Hepatitis C/diagnosis , Hepatitis C/mortality , Hepatitis C/epidemiology , Hepatitis B/diagnosis , Hepatitis B/mortality , Hepatitis B/epidemiologyABSTRACT
El nuevo tratamiento simplificado con antivirales orales para pacientes con Hepatitis C puede ser abordado desde la atención primaria, lo que facilita el acceso de la población afectada por esta infección crónica. En este artículo se repasan los aspectos claves del diagnóstico, el esquema de tratamiento simplificado y los candidatos a recibirlo. (AU)
The new simplified treatment with oral antivirals for hepatitis C patients can be approached at the primary care level, facilitating access for the population affected by this chronic infection. This article reviews the key aspects of the diagnosis, the simplified treatment scheme, and the eligible candidates for the treatment. (AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Antiviral Agents/administration & dosage , Hepatitis C/diagnosis , Hepatitis C/drug therapy , Primary Health Care , Enzyme-Linked Immunosorbent Assay , Hepatitis C/blood , Persistent Infection/diagnosis , Persistent Infection/drug therapy , Persistent Infection/blood , Liver Cirrhosis/diagnosisABSTRACT
ABSTRACT OBJECTIVE To determine the seroprevalence of hepatitis B and C among immigrants residing refugee camps in Muzaffarabad, Azad Kashmir, Pakistan, and to identify possible risk factors for hepatitis B virus (HBV) and hepatitis C virus (HCV) transmission. METHODS Around 1,225 individuals inhabiting Muzaffarabad refugee camps, participated in the study. A qualitative Immuno-Chromatographic Technique was used for initial screening and PCR test was used for detection of HBV and HCV in participants. The major risk factors for HBV and HCV transmission were assessed using a questionnaire approach. RESULTS Around 86 (7.0%) individuals were observed for hepatitis B surface antigen (HBsAg) presence, and 215 (17.5%) individuals were found positive for Anti-HCV. Only 32 (2.6%) individuals were confirmed for HBV DNA and 126 (10.3%) individuals were positive for HCV RNA after PCR. Demographically, both HBsAg and Anti-HCV were found more prevalent in female (4.4% HBsAg and 10.8% Anti-HCV) population as compared to male (2.6% HBsAg and 6.7% Anti-HCV) population. Surprisingly, the HBsAg (23.5%) and Anti-HCV (41.1%) appeared to be more frequent in the age group 62-75 years. Previous history of hepatitis in the family (p < 0.0001), blood transfusion (p = 0.0197) dental treatment (p < 0.0001) and tattooing or piercing on any part of the body (p = 0.0028) were assessed as significant risk factors in HBV and HCV transmission. CONCLUSIONS Presence of 7.0% HBsAg and 17.5% Anti-HCV in a small fragment of the migrant population cannot be overlooked. Lack of awareness among people and negligence of health department could escalate the situation.
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Refugees , Hepatitis C/diagnosis , Hepatitis C/epidemiology , Hepatitis B/epidemiology , Pakistan/epidemiology , Brazil , Seroepidemiologic Studies , Hepatitis B virus/genetics , Hepacivirus/genetics , Hepatitis C Antibodies , Hepatitis B Surface AntigensABSTRACT
Se describe los casos de tres pacientes a quien se les realiza diagnóstico de colestasis intrahepática del embarazo (CIE) de aparición temprana. En dos de ellos el diagnóstico se relacionó con infección por el virus de la hepatitis C (VHC). Reconocer que esta enfermedad puede presentarse de manera temprana en el embarazo y su relación con la infección por el VHC es fundamental para hacer un diagnóstico oportuno de ambas enfermedades y tomar las conductas terapéuticas adecuadas, mejorando así el pronóstico materno y fetal.
It is of great importance to acknowledge that this disease can occur early in pregnancy and that its relationship with HCV infection is a key point for a prompt diagnosis, allowing taking timely appropriate therapeutic decisions, aimed at improving the fetal prognosis.
Descrevemos os casos de três pacientes com diagnóstico de colestase intra-hepática da gravidez de início precoce. Em dois deles o diagnóstico estava relacionado à infecção pelo vírus da hepatite C (VHC). Reconhecer que esta doença pode se manifestar precocemente na gravidez e sua relação com a infecção pelo VHC é fundamental para fazer um diagnóstico oportuno de ambas as doenças e assumir condutas terapêuticas adequadas, melhorando assim o prognóstico materno e fetal.
Subject(s)
Humans , Female , Pregnancy , Adult , Pregnancy Complications, Infectious/diagnosis , Pruritus , Cholestasis, Intrahepatic/diagnosis , Cholestasis, Intrahepatic/etiology , Hepatitis C/complications , Pregnancy Trimester, Second , Pregnancy Trimester, First , Ursodeoxycholic Acid/therapeutic use , Chlorpheniramine/therapeutic use , Cholestasis, Intrahepatic/drug therapy , Hepatitis C/diagnosis , Early DiagnosisABSTRACT
SUMMARY OBJECTIVE: This study aimed to compare the serum samples found reactive (≥1-≤20 signal-to-cutoff ratio) with Elecsys antibodies to hepatitis C virus screening test with innogenetics-line immunassay hepatitis C Virus Score test and to determine the most appropriate threshold value for our country, since positive results close to the cutoff value cause serious problems in routine diagnostic laboratories. METHODS: Antibodies to hepatitis C virus-positive samples from 687 different patients were included in the study. Antibodies to hepatitis C virus antibody detection was performed using Elecsys antibodies to hepatitis C virus II kits (Roche Diagnostics, Germany), an electrochemiluminescence method based on the double-antigen sandwich principle, on the Cobas e601 analyzer (Roche Diagnostics) in accordance with the recommendations of the manufacturer. Samples that were initially identified as reactive were studied again. Samples with ≥1-≤20 signal-to-cutoff ratio reagents as a result of retest were included in the study to be validated with the third-Generation Line immunassay kit (innogenetics-line immunassay hepatitis C Virus, Belgium). RESULTS: A total of 687 samples with antibodies to hepatitis C virus positive and levels between 1-20 S/Co were found to be 56.1% negative, 14.8% indeterminate, and 29.1% positive by innogenetics-line immunassay hepatitis C Virus confirmation test. When the cases with indeterminate innogenetics-line immunassay hepatitis C Virus test results were accepted as positive, the signal-to-cutoff ratio value for antibodies to hepatitis C virus was determined as 5.8 (95% confidence interval) in distinguishing the innogenetics-line immunassay hepatitis C Virus negative and positive groups. CONCLUSION: It was concluded that with further studies on this subject, each country should determine the most appropriate S/Co value for its population, and thus it would be beneficial to reduce the problems such as test repetition and cost increase.
Subject(s)
Humans , Hepatitis C/diagnosis , Hepatitis C Antibodies , Immunoassay , Sensitivity and Specificity , Hepacivirus/geneticsABSTRACT
INTRODUCCIÓN: La medición de carga viral (CV) de virus hepatitis B (VHB) y C (VHC) es fundamental en el seguimiento de pacientes con terapia antiviral. La metodología más utilizada para su determinación es COBAS ®-TaqMan ®. Recientemente, se desarrolló la tecnología Xpert ®, que se debe evaluar. OBJETIVO: Comparar la medición de la CV de VHB y VHC por metodología Xpert® con COBAS®-TaqMan® como método de referencia. MATERIAL Y MÉTODOS: 39 muestras de suero de pacientes con VHB y 39 con VHC, previamente cuantificadas por COBAS ®-TaqMan ®, fueron analizadas mediante Xpert® y los resultados se compararon utilizando la regresión de Deming y gráfico Bland-Altman. RESULTADOS: Hubo una alta correlación entre Xpert® y COBAS®-TaqMan®. Para VHB, la ecuación de Deming fue XpertHBV = 0,44 + 0,99xCOBASTaqManHBV, con coeficiente de correlación de 0,94 y diferencia entre medias de -0,401 log10 (IC95%: -1,985 a 1,183). Para VHC, la ecuación de Deming fue XpertHCV = 0,36 + 0,87x COBASTaqManHCV, con coeficiente de correlación de 0,98 y diferencia entre medias de 0,328 log (IC95%: -0,449 a 1,105). CONCLUSIÓN: El nuevo sistema Xpert® muestra una buena correlación con COBAS ®-TaqMan ® para la medición de la CV de VHB y VHC, siendo una buena alternativa para el seguimiento de pacientes en tratamiento.
BACKGROUND: The measurement of viral load (VL) of hepatitis B (HBV) and C (HCV) viruses is essential in the follow-up of patients with antiviral therapy. The most widely used methodology for this determination is COBAS®-TaqMan®. Recently, the Xpert® technology was developed and needs to be evaluated. AIM: To compare the measurement of the VL of HBV and HCV by Xpert® methodology with COBAS®-TaqMan® as a reference method. MATERIAL AND METHODS: 39 serum samples from patients with HBV and 39 with HCV, previously quantified by COBAS®-TaqMan®, were analyzed using Xpert® and the results were compared using Deming regression and Bland-Altman plot. RESULTS: There was a high correlation between Xpert® and COBAS®-TaqMan®. For HBV, the Deming equation was XpertHBV = 0.44 + 0.99xCOBASTaqManHBV, with a correlation coefficient of 0.94 and a difference between means of -0.401 log (95% CI: -1.985 to 1.183). For HCV, the Deming equation was XpertHCV = 0.36 + 0.87x COBASTaqManHCV, with a correlation coefficient of 0.98 and a difference between means of0.328 log10 (95% CI: -0.449 to 1.105). CONCLUSION: The new Xpert® system shows a good correlation with COBAS®-TaqMan® for the measurement of the VL of HBV and HCV, being a good alternative for the follow-up of patients under treatment.
Subject(s)
Humans , Hepatitis C/diagnosis , Hepatitis B/diagnosis , RNA, Viral , Hepatitis B virus/genetics , Sensitivity and Specificity , Hepacivirus/genetics , Viral LoadABSTRACT
ABSTRACT BACKGROUND: Viral hepatitis is a global phenomenon, with the disease burden varying on a daily basis. Amongst chronic infections, hepatitis B virus and hepatitis C virus (HCV) are egregiously linked to severe health-related complications, with a worldwide prevalence of 248 million and 71 million respectively. Amongst the developing world, a hand full of countries are exhibiting a gross decline in chronic viral infection prevalence, like Bangladesh. While countries such as India have a consistent prevalence, Pakistan bears one of the largest proportions of chronic viral hepatitis globally with increasing trends shown year-by-year. Various old literature texts have stated an approximate national prevalence rate around 2.6% and 5.3% of hepatitis B and C respectively. OBJECTIVE: The objective of this study was to determine the current seroprevalence rates of chronic viral hepatitis amongst the general population of rural Sindh using a screening program to determine the current disease burden. METHODS: An observational, cross-sectional survey based on a screening program was conducted in 5 districts with a combined population of over 6.5 million. The screening was carried out via the administration of various camps with the assistance of local social workers and welfare organizations. A total of 24,322 individuals met the inclusion criteria and were screened through (HBsAg/HCV) rapid test cassette (WC) Imu-Med one-step diagnostic test. RESULTS: Hepatitis B was found positive in 964 (3.96%) individuals including 421 (43.67%) males and 543 (56.32%) females, while hepatitis C was positive in 2872 (11.80%) individuals including 1474 (51.32%) males and 1398 (48.67%) females. The prevalence amongst the districts varied between 0.97% and 9.06% for hepatitis B, and 1.61% and 29.50% for hepatitis C, respectively. Umerkot was found to be the most prevalent district amongst rural Sindh, while Badin had the least number of seropositive people. The second most prevalent district of the study population was found to be Tando Allahyar followed by Mirpur Khas. The combined seroprevalence of 15.76% was calculated for hepatitis B and C together amongst the five studied districts of rural and peri-urban Sindh. CONCLUSION: The alarmingly high prevalence rates revealed in our study warrant the urgent need to generate multiple effective strategies in the region to enhance awareness amongst the general population regarding screening, prevention, and prompt treatment of the disease.
RESUMO CONTEXTO: A hepatite viral é um fenômeno global, com a intensidade da doença variando diariamente. Entre as infecções crônicas, o vírus da hepatite B e o vírus da hepatite C (VHC) estão fortemente ligados a complicações graves relacionadas à saúde, com prevalência mundial de 248 milhões e 71 milhões, respectivamente. Entre o mundo em desenvolvimento, uma quantidade de países está exibindo um declínio bruto na prevalência de infecção viral crônica, tal como Bangladesh. Embora países como a Índia tenham uma prevalência consistente, o Paquistão tem uma das maiores proporções globais de hepatite viral crônica, com tendências crescentes mostradas ano a ano. Vários textos da menos recentes têm declarado uma taxa de prevalência nacional aproximada em torno de 2,6% e 5,3% da hepatite B e C, respectivamente. OBJETIVO: O objetivo deste estudo foi determinar as atuais taxas de soroprevalência da hepatite viral crônica entre a população geral do Sindh rural utilizando um programa de triagem para determinar a carga atual da doença. MÉTODOS: Foi realizada uma pesquisa observacional e transversal baseada em um programa de triagem combinada em cinco distritos com população de mais de 6,5 milhões. A triagem foi realizada por meio da administração de diversos acampamentos com o auxílio de assistentes sociais locais e organizações de assistência social. Um total de 24.322 indivíduos atenderam aos critérios de inclusão e foram examinados através do teste rápido (HBsAg/VHC) Imu-Med em uma etapa. RESULTADOS: Hepatite B positiva foi encontrada em 964 (3,96%) indivíduos incluindo 421 (43,67%) homens e 543 (56,32%) mulheres, enquanto hepatite C foi positiva em 2.872 (11,80%) indivíduos incluindo 1.474 (51,32%) homens e 1.398 (48,67%) mulheres. A prevalência entre os distritos variou entre 0,97% e 9,06% para hepatite B, e 1,61% e 29,50% para hepatite C, respectivamente. Umerkot foi encontrado como o distrito mais prevalente entre Sindh rural, enquanto Badin tinha o menor número de pessoas soropositivas. O segundo distrito mais prevalente da população de estudos foi encontrado como Tando Allahyar, seguido por Mirpur Khas. A soroprevalência combinada de 15,76% foi calculada para hepatite B e C em conjunto entre os cinco distritos estudados do Sindh rural e periurbano. CONCLUSÃO: As taxas de prevalência alarmantemente reveladas em nosso estudo justificam a necessidade urgente de gerar múltiplas estratégias efetivas na região para aumentar a conscientização da população em geral sobre rastreamento, prevenção e tratamento rápido da doença.
Subject(s)
Humans , Male , Female , Hepatitis C/diagnosis , Hepatitis C/epidemiology , Hepatitis B/diagnosis , Hepatitis B/epidemiology , Pakistan/epidemiology , Seroepidemiologic Studies , Prevalence , Cross-Sectional StudiesABSTRACT
Resumen La principal infección viral transmisible por sangre es actualmente la debida al virus de hepatitis C (VHC). Uno de los mayores obstáculos para el logro de su control en la Argentina se relaciona con las dificultades de acceso al diagnóstico y tratamiento oportuno de las personas infectadas. Este estudio se realizó con el objetivo de caracterizar a los pacientes infectados con VHC que iniciaron tratamiento con antivirales de acción directa (AAD) y describir la experiencia vinculada al tratamiento. Se seleccionaron las historias clínicas de 82 pacientes, 44 (53.7%) de sexo masculino, 37 (45.1%) de sexo femenino, y uno (1.2%) transgénero. La media de edad fue de 49 años. Se halló una frecuencia de cirrosis de 39%, 32 pacientes, coinfección con HIV en 48 (58.5%) y con VHB en 27 (32.9%). En 52 (63.4%) no se observó ningún factor de riesgo claramente asociado a infección. Todos completaron la terapia, de ellos 72 (87.8%) efectuaron el control para confirmar respuesta viral sostenida (RVS), que fue de 98.6%. Concluimos que el testeo universal debe implementarse por sobre el testeo con enfoque de riesgo, y que debe promoverse un criterio de atención simplificado y descentralizado, reservando la atención especializada para pacientes con cirrosis descompensada y cáncer de hígado.
Abstract Hepatitis C virus (HCV) infection is currently the main blood-borne viral infection. One of the main obstacles to achieving its control in Argentina is related to difficulties in accessing the diagnosis and timely treatment of infected people. We carried out this study with the aim of characterizing the HCV-infected patients who started treatment with direct-acting antivirals (DAAs) and to describe the experience related to treatment. The medical records of 82 patients, 44 (53.7%) male, 37 (45.1%) female, and one (1.2%) transgender, were selected. The mean age was 49 years. We report a frequency of cirrhosis, 39%, in 32 patients, coinfection with HIV in 48 (58.5%) and with HBV in 27 (32.9%). In 52 patients (63.4%), no risk factor clearly associated with infection was observed. All completed the therapy, of them 72 (87.8%) carried out the control to confirm sustained viral response (SVR), that attained 98.6%. We conclude that universal testing should be implemented over testing based on a risk approach, and that a simplified and decentralized care criterion should be promoted, reserving specialized care for patients with decompensated cirrhosis and liver cancer.
Subject(s)
Humans , Male , Female , Middle Aged , Antiviral Agents/therapeutic use , HIV Infections/drug therapy , Hepatitis C/diagnosis , Hepatitis C/drug therapy , Hepatitis C/epidemiology , Hepatitis C, Chronic/drug therapy , Coinfection/epidemiology , Argentina/epidemiology , Hepacivirus , Liver CirrhosisABSTRACT
Objective@#The aim of the present study was to evaluate the performance of the simultaneous detection of HIV-1 RNA, HIV-1 DNA, and HCV RNA using one dried blood spot (DBS) as an alternative sample to plasma.@*Method@#A total of 571 paired DBS/plasma samples were collected from men who have sex with men (MSM) and injection drug users (IDUs), and serological and molecular assays were performed. Using plasma results as the reference standard, the performance of DBS tests for HIV-1 RNA, HIV-1 DNA, and HCV RNA was evaluated. Pearson's correlation coefficients and Bland-Altman analysis were performed to assess the correlation and concordance between DBS and plasma.@*Results@#Among paired plasma/DBS samples with detectable HIV-1 RNA and HCV RNA, five samples (5/32) were not detectable in DBS, while measurable HIV-1 RNA levels were present in plasma (1.44 to 3.99 log @*Conclusion@#The performance of the simultaneous detection of HIV-1 RNA, HIV-1 DNA, and HCV RNA using one DBS was acceptable. DBS, as an alternative sample to plasma, may be a viable option for the simultaneous detection of HIV-1 RNA, HIV-1 DNA, and HCV RNA in resource-limited settings or for individuals living in areas that are difficult to access.
Subject(s)
DNA, Viral/analysis , Diagnostic Tests, Routine/methods , Dried Blood Spot Testing/methods , HIV Infections/diagnosis , HIV-1/isolation & purification , Hepacivirus/isolation & purification , Hepatitis C/diagnosis , RNA, Viral/analysis , Sensitivity and Specificity , Specimen Handling/methods , Syphilis/diagnosis , Treponema pallidum/isolation & purificationABSTRACT
Abstract This article discusses viral hepatitis, a theme addressed by the Clinical Protocol and Therapeutic Guidelines to Comprehensive Care for People with Sexually Transmitted Infections and, more precisely, by the Clinical Protocols and Therapeutic Guidelines for Hepatitis B and Hepatitis C and Coinfections, published by the Brazilian Ministry of Health. Besides the broad spectrum of health impairment, hepatitis A, B, and C viruses also present different transmission forms, whether parenteral, sexual, vertical, or fecal-oral. Among the strategies suggested for the control of viral hepatitis, in addition to behavioral measures, are expanded diagnosis, early vaccination against hepatitis A and hepatitis B viruses, and access to available therapeutic resources. Considering vertical transmission of the hepatitis B and hepatitis C viruses, screening for pregnant women with chronic hepatitis B and C is an essential perinatal health strategy, indicating with precision those who can benefit from the prophylactic interventions.
Subject(s)
Humans , Female , Pregnancy , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/prevention & control , Hepatitis C/diagnosis , Hepatitis C/prevention & control , Hepatitis B/diagnosis , Hepatitis B/prevention & control , Brazil , Infectious Disease Transmission, Vertical/prevention & controlABSTRACT
Abstract INTRODUCTION: We compared the hepatitis C virus (HCV) core antigen test with the HCV RNA assay to confirm anti-HCV results to determine whether the HCV core antigen test could be used as an alternative confirmatory test to the HCV RNA test. METHODS: Sera from 156 patients were analyzed for anti-HCV and HCV core antigen using a chemiluminescent microparticle immunoassay (Architect i2000SR) and for HCV RNA using the artus HCV RG RT-PCR Kit (QIAGEN) in a Rotor-Gene Q instrument. RESULTS: The diagnostic sensitivity, specificity, and positive and negative predictive values of the HCV core antigen assay compared to the HCV RNA test were 77.35%, 100%, 100%, and 89.38%, respectively. HCV core antigen levels showed a good correlation with those from HCV RNA quantification (r =0.872). However, 13 samples with a viral load of less than 4000 IU/mL were negative in the HCV core antigen assay. All gray-zone reactive samples were also RNA positive and were positive on repeat testing. CONCLUSIONS: The Architect HCV core antigen assay is highly specific and has an excellent positive predictive value. At the present level of sensitivity (77%), the study is still relevant in a low-income setting in which most of the HCV-positive patients would go undiagnosed, since HCV RNA testing is not available and/or not affordable. HCV core antigen testing can also help determine the true burden of infection in a population, considering the fact that almost 50% of the anti-HCV positive cases are negative for HCV RNA.
Subject(s)
Humans , Hepatitis C/diagnosis , Hepacivirus/genetics , RNA, Viral , Sensitivity and Specificity , Hepatitis C Antigens , Hepatitis C AntibodiesABSTRACT
ABSTRACT Introduction: Hepatitis C virus (HCV) infection continues to be an important public health problem worldwide. Despite the availability of drugs that promote the cure of infection in more than 95% of cases, the identification of HCV carriers remains a major challenge. Objective: To evaluate a strategy for identifying HCV carriers based on combined criteria: screening in emergency units and specialty outpatient clinics of a tertiary hospital and among older adults (≥45 years), both suggested as efficient in epidemiological studies. Methods: A cross-sectional, analytical and descriptive study was conducted on individuals of both sexes, aged 45 years and older, attending the emergency department and specialty outpatient clinics of a University Hospital in São Paulo, Brazil, from January 2016 to June 2018. After giving formal consent, the patients were submitted to a standardized interview and rapid testing for the identification of HCV antibodies (SD BIOLINE® anti-HCV). Results: A total of 606 adult patients (62% women and 37% men) were evaluated. The mean age was 62 ± 10 years. Four positive tests were identified, with confirmation by conventional serology and HCV-RNA determination. Thus, the prevalence of HCV identified in the sample was 0.66%. All patients had a history of risk factors for infection. Conclusion: The strategies of birth-cohort testing and screening in emergency medical services for the identification of HCV carries, both suggested in the literature as efficient for the diagnosis of hepatitis C, resulted in a low rate of HCV infection. These findings highlight the magnitude of the challenge of identifying asymptomatic HCV carriers in Brazil.
Subject(s)
Humans , Male , Female , Aged , Hepatitis C/diagnosis , Hepatitis C/epidemiology , Hepacivirus/genetics , Outpatients , Brazil/epidemiology , Prevalence , Cross-Sectional Studies , Hepatitis C Antibodies , Emergency Service, Hospital , Middle AgedABSTRACT
Hepatitis C virus infection is a major global public health problem. Treatment with direct-acting antivirals is intended to eradicate the chronic form of this infection by 2030. Although uncommon, the acute form of presentation is increasingly recognized, especially in some high-risk populations, such as men who have sex with men without protection. Its virological and serological diagnosis is not standardized, so clinical suspicion is essential. Its early detection allows a timely treatment. We report seven cases of acute HCV hepatitis in a national reference center, its presentation, diagnosis and treatment. We discuss populations at risk and the change in therapeutics with the use of direct-acting antiviral drugs.
Subject(s)
Humans , Male , Hepatitis C , Hepatitis C, Chronic , Sexual and Gender Minorities , Antiviral Agents/therapeutic use , Hepatitis C/diagnosis , Hepatitis C/drug therapy , Homosexuality, Male , Hepatitis C, Chronic/drug therapyABSTRACT
RESUMEN Introducción: la cirrosis es un proceso dinámico y actualmente se conoce que cuando se elimina el agente primario de agresión que ha producido la cirrosis, se puede llegar a remitir la fibrosis. En Cuba la enfermedad representa la décima causa de muerte, con una tendencia ascendente en los últimos 20 años y una tasa de 13,4 por 100 000 habitantes. Objetivo: caracterizar clínica y endoscópicamente a pacientes con diagnóstico de cirrosis hepática. Material y método: se realizó un estudio descriptivo transversal, en el período comprendido entre los años 2017 - 19, donde el universo y la muestra quedaron constituidos por todos los pacientes mayores de 18 años ingresados con diagnóstico de cirrosis hepática. Resultados: predominó el sexo masculino en la sexta década de la vida, siento la principal causa el alcoholismo, caracterizado por manifestaciones generales, que en muchos casos debutan por complicaciones, apareciendo várices esofágicas en el 75 % de los casos, aunque gados I y II de Paquet, dependiente a un diagnóstico precoz de la enfermedad. Conclusiones: el alcoholismo crónico es la causa más frecuente de cirrosis hepática, debuta de forma frecuente por sus complicaciones, aunque el diagnóstico se hace en etapas precoces, con varices esofágicas incipientes (AU).
Summary Introduction: liver cirrhosis is a dynamic process and currently it is known that, when the primary agent of aggression that has produced the cirrhosis is eliminated, the fibrosis could remit. In Cuba, this diseases is the tenth cause of death, with an increasing tendency in the last twenty years and a rate of 13.4 per 100 000 inhabitants. Objective: to characterize, clinically and endoscopically, patients with hepatic cirrhosis diagnosis. Material and methods: a cross-sectional descriptive study was carried out, in the period 2017 - 2019, where the universe and the sample were formed by all the patients aged more than 18 years who entered the hospital with diagnosis of liver cirrhosis. Results: in this paper, male patients in their sixties predominated, being alcoholism the main cause of disease, characterized by general manifestations; patients debuted due to complications, appearing esophageal varices in 75 % of the cases, although Paquet I and II grades, in dependence to a disease precocious diagnosis. Conclusions: the authors concluded that chronic alcoholism is the most frequent cause in hepatic cirrhosis, almost always debuting by its complications, though the diagnosis is made in precocious stages, with emerging esophageal varices (AU).
Subject(s)
Humans , Adolescent , Esophageal and Gastric Varices/complications , Liver Cirrhosis/diagnosis , Ascites/complications , Epidemiology, Descriptive , Cross-Sectional Studies , Hepatitis C/diagnosis , Alcoholism/complications , Endoscopy , Hepatitis B/diagnosis , Liver Cirrhosis/epidemiologySubject(s)
Male , Female , Pregnancy , Infant, Newborn , Prenatal Care/methods , Prenatal Diagnosis/methods , Parasitic Diseases/diagnosis , Thyroid Diseases/diagnosis , Urinary Tract Infections/diagnosis , Syphilis/diagnosis , HIV Infections/diagnosis , Uterine Cervical Neoplasms/diagnosis , Toxoplasmosis/diet therapy , Clinical Protocols , Communicable Diseases/diagnosis , Hepatitis C/diagnosis , Hepatitis C/diagnostic imaging , Cytomegalovirus Infections/diagnosis , Infectious Disease Transmission, Vertical , Clinical Laboratory Techniques , Diabetes Mellitus/diagnosis , Medication Therapy Management , Neonatal Sepsis/diagnosis , Hemoglobinopathies/diagnosis , Hepatitis B/diagnosis , Hepatitis B/diagnostic imaging , Anemia/diagnosis , Measles/diagnosisSubject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Young Adult , Hepatitis C/diagnosis , Hepatitis C/virology , Hepacivirus/pathogenicity , Antiviral Agents/therapeutic use , Serologic Tests , Polymerase Chain Reaction , Patient Education as Topic , Risk Factors , Hepatitis C/prevention & control , Hepatitis C/epidemiology , Hepatitis C Antibodies/analysis , Patient PreferenceABSTRACT
Introdução: A hemoterapia consiste no tratamento terapêutico através da transfusão sanguínea. Considerando à vasta quantidade de doenças infecciosas que podem ser transmitidas pelo sangue, se faz necessária a realização de exames laboratoriais de alta sensibilidade para minimizar os riscos transfusionais aos doadores e receptores. Assim, no estudo foi avaliada a prevalência de marcadores sorológicos para Hepatite B e C em um banco de sangue de Porto Alegre- RS, bem como a correlação entre a sorologia e o teste de amplificação de ácido nucléico (NAT). Métodos: Estudo quantitativo, descritivo e retrospectivo que foi realizado através da análise das informações de todos os doadores de sangue contidas em um banco de dados de um Banco de Sangue de Porto Alegre, Rio Grande do Sul, nos anos de 2017 e 2018, avaliando resultados da sorologia e o teste NAT para hepatite B e Hepatite C. Resultados: Das 17.181 doações de sangue, o total de bolsas sorologicamente reagentes foi 162 (0,94%) reagentes para o Anti-HBc, 20 (0,12%) amostras foram positivas para o HbsAg e 62 (0,36%) reagentes para o Anti-HCV. Apenas 4 (0,02%) amostras foram reagentes simultaneamente para o Anti-HBC e para o HbsAg, as quais foram também positivas no teste NAT. Já o teste NAT nas amostras reagente para Hepatite C, corresponderam a 18 (0,10%). Conclusões: A evolução da biotecnologia vem auxiliando a biossegurança nas transfusões de sangue. Considerando que a implementação do teste NAT é relativamente recente nos bancos de sangue, sugere-se mais estudos com períodos diferentes de tempo para a pesquisa de resultados satisfatórios, além disso, possibilitando elucidar ainda mais os resultados voltados à segurança transfusional e a associação dos testes sorológicos e o teste NAT nos bancos de sangue. (AU)
Introduction: Hemotherapy consists of therapeutic treatment using blood transfusion. Because of the vast amount of bloodborne infectious diseases, highly sensitive laboratory tests must be conducted to minimize the transfusion risks for donors and recipients. Thus, the present study aimed to evaluate the prevalence of hepatitis B and C serological markers in samples from a blood bank in Porto Alegre, southern Brazil, as well as the correlation between serology and nucleic acid amplification testing (NAT). Methods: A quantitative, descriptive, retrospective study was conducted to analyze blood donor information obtained from a blood bank database in Porto Alegre, southern Brazil, concerning 2017 and 2018. Serology and NAT results for hepatitis B and C were examined. Results: Of 17,181 blood donations, the total number of serologically reactive samples was 162 (0.94%) for anti-HBc, 20 (0.12%) for HbsAg, and 62 (0.36%) for anti-HCV. Only 4 (0.02%) samples were simultaneously reactive for anti-HBc and HbsAg, being also positive in NAT. The number of samples reactive to hepatitis C in NAT was 18 (0.10%). Conclusions: Biotechnological evolution has contributed to biosafety in blood transfusions. Considering that NAT is relatively recent in blood banks, further studies using different time periods are suggested for yielding satisfactory results for transfusion safety and elucidating the combination of serological testing and NAT at blood banks. (AU)
Subject(s)
Humans , Serology , Blood Banks/methods , Hepatitis C/diagnosis , Hepatitis B/diagnosis , Communicable Diseases/diagnosis , Retrospective StudiesABSTRACT
Abstract According to data from the last census of the Brazilian Society of Nephrology (SBN), the prevalence of hepatitis C virus (HCV) in Brazilian hemodialysis units (HU) is 3.3%, about three times higher than what is reported for the Brazilian general population. Often, professionals working in HU are faced with clinical situations that require rapid HCV diagnosis in order to avoid horizontal transmission within the units. On the other hand, thanks to the development of new antiviral drugs, the cure of patients with HCV, both in the general population and in patients with chronic kidney disease and the disease eradication, appear to be very feasible objectives to be achieved in the near future . In this scenario, SBN and the Brazilian Society of Hepatology present in this review article a proposal to approach HCV within HUs.
Resumo De acordo com os dados do último censo da Sociedade Brasileira de Nefrologia (SBN), a prevalência de portadores do vírus da hepatite C (HCV) nas unidades de hemodiálise (UH) no Brasil é de 3,3%, cerca de três vezes maior do que é observado na população geral brasileira. Muitas vezes, os profissionais que trabalham nas UH deparam-se com situações clínicas que demandam rápido diagnóstico do HCV, a fim de evitar uma transmissão horizontal dentro das unidades. Por outro lado, a cura dos pacientes portadores do HCV, tanto na população geral como na portadora de doença renal crônica e a erradicação da doença, em virtude do desenvolvimento de novas drogas antivirais, parecem ser objetivos bastante factíveis, a ser alcançados em futuro próximo. Nesse cenário, a SBN e a Sociedade Brasileira de Hepatologia apresentam neste artigo de revisão uma proposta de abordagem do HCV dentro das UH.
Subject(s)
Humans , Renal Dialysis/statistics & numerical data , Hepatitis C/epidemiology , Disease Transmission, Infectious/prevention & control , Renal Insufficiency, Chronic/therapy , Antiviral Agents/therapeutic use , RNA Viruses/genetics , Brazil/epidemiology , Cross Infection/transmission , Prevalence , Hepatitis C/diagnosis , Hepatitis C/drug therapy , Hepacivirus/drug effects , Hepacivirus/genetics , Glomerular Filtration Rate/physiology , Nephrology/organization & administration , Nephrology/statistics & numerical dataABSTRACT
Resumen: En el escenario de la salud mexicana, la epidemia por virus de la hepatitis C se encuentra presente junto con sus comorbilidades y mortalidad prematura. Actuar de manera inmediata permitirá una contención de la misma en el corto plazo dada la existencia de herramientas de prevención, diagnóstico y terapias farmacológicas altamente eficaces. La Coalición para el estudio de la hepatitis C en México ha desarrollado una postura donde aprovecha esas medidas de contención y presenta el desarrollo de un programa nacional para la detección, tratamiento oportuno y seguimiento de pacientes con hepatitis C.
Abstract: In the Mexican health scenario, the hepatitis C virus epidemic is present, along with its comorbidities and premature mortality. Acting immediately will allow its containment in short term with the proper implementation of the current available tools for prevention, diagnosis and highly effective pharmacological therapies. The Coalition for the study of hepatitis C in Mexico has developed a position paper that takes advantage of these containment measures and presents the development of a National program for the detection, timely treatment and follow-up of patients with hepatitis C.